<DOC>
	<DOCNO>NCT01341613</DOCNO>
	<brief_summary>Background : It become increasingly clear individual corner globe use probiotic dietary approach enhance health . More recently , probiotic show promise treat variety disease state , due improve strain selection , stability delivery technology . Objective : The purpose study determine lipid lower efficacy probiotic supplement capsule contain Lactobacillus reuteri Cardioviva™ , take twice per day 9 week , subject hypercholesterolemia . Design : The study design double-blinded , placebo-controlled , randomize , parallel-arm , multi-centre study . The study last total 13 week , include 2-week wash-out period , 2-week run-in period 9 week treatment period .</brief_summary>
	<brief_title>Efficacy Cardioviva™ Probiotic Supplement Capsule Formulation</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Males female , age 20 75 year ( bound include ) LDLCholesterol 3.4 mmol/L ( &lt; 15 % variation visit V1 V21 ) TG level 4.0 mmol/L ( checked visit V0 V21 ) BMI range 22 32 kg/m² Subject understand accepts follow dietary recommendation advisable hypercholesterolemic patient ( accord NCEPATP III guideline ) For subject statin monotherapy : dosage statin must stable least 3 month prior study begin ( 1520 % subject ) Judged investigator compliant ( &gt; 80 % ) product consumption ( check V21 ) , motivate Signed inform consent form prior inclusion study Note : Subjects permit take stable dos thyroid hormone antihypertensive agent , long continue equivalently throughout duration study For female subject : effective contraceptive method use Use cholesterol lower prescription drug statin monotherapy within last 6 month Use plant sterol , omega 3 , fish oil , soy protein , soluble oat fiber , psyllium seed husk , cholesterol lower nonprescription food supplement within last 3 month History chronic use alcohol ( &gt; 2 drinks/d ) Use systemic antibody , corticosteroid , androgen , phenytoin Subject experience cardiovascular event ( Myocardial infarction , coronary artery bypass , major surgical procedure ) last 6 month Diabetic subject ( Type I Type II ) Subject receive systemic treatment topical treatment likely interfere evaluation study parameter Subject currently involve clinical trial exclusion period follow participation another clinical trial History angina , congestive heart failure , inflammatory bowel disease , pancreatitis , gastrointestinal , renal , pulmonary , hepatic biliary disease , cancer ( evidence active lesion , chemotherapy surgery past year ) Chronic user probiotic fibre laxative ( great 2 doses/wk ) , stimulant laxatives History eat disorder Exercise great 15 miles/wk 4,000 kcal/wk For female subject : Pregnancy , breast feeding , intent get pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>